#ILCA26 is supporting the next generation of liver cancer experts! We are offering free student registrations and travel grants for Brussels this September. Key details: ➡️Under 35 & an ILCA member ➡️First come, first served! ➡️Deadline: 29th June 2026 🔗ilcalive.org/annual-conferen…

Top trending women GI cancer oncologists on 𝕏 during @ASCO 2026. Ranked by views of oncologist posts on clinical trials. Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer | @GillSharlene | @coffman_kelley | @DraMartinezLago | @NiuSanford | @DrAngelaLamarca | @CathyEngMD | @graokane | @rutikamehtaMD | @rachnatshroff | @drallysonocean

Novel MEK1/2i (atebimetinib) GnP 1L #PDAC;single arm ph2 Drug anticachexia properties ➡️36% peritoneal met; 50%Liver ➡️n=55; ORR 42% 50pts median FU 10.4mths ➡️mPFS 8.3 mths,mOS 17.3mth ➡️manageable tox; combo strategies? ✅Ph3 MAPKeeper301 recruiting #ASCO26 @OncoAlert @ASCO

SWOG S2001:maintenance olaparib/pembro v olaparib gBRCA1/2 #PDAC ➡️closed due to futility ➡️n = 73 mPFS 8.2 v6.4mths ➡️mOS 20 v 22.1mths Higher ORR but need understand TiME HRD-PDAC better for better combo! #ASCO26 @ASCO @OncoAlert @pancanireland @KReissMD

Great discussion by @StephenLChan1 on new phase 3 studies of #immunotherapy combinations for #HCC at #ASCO26. How to combine in the intermediate stage and sequence in the advanced stage. @ASCO

1st-line QLS31905 chemo in #PDAC & gastric ca -phase 1b/2 study. ➡️Claudin 18.2/CD3 Bispecific ➡️N=88 PDAC N=43 Gastric ca, ➡️82 PDAC pts mPFS 8.7 &mOS 15.9, ➡️43 GC pts mPFS 10.1 mths &mOS NR ✅tolerable & v promising activity! #ASCO26 @ASCO @OncoAlert

Phase 3 IMbrave251:#ASCO26 Atezo/Len or Sora v Len/Sora 2nd line post atezo/bev ➡️Mostly Lenvatinib (92%) ➡️mOS 14.6 v 12.5; mPFS 4.3 v 4.8 ❎no role continue PD-L1i in 2nd line while switching to TKI➡️similar other ca  ✅new benchmark OS 2nd-line @ASCO @ILCAnews @OncoAlert

EMERALD-3: STRIDE/Len/TACE v STRIDE TACE v TACE #HCC #ASCO26 N=760 , prim endpoint PFS arm A v C(multiple testing) ➡️ includes BCLC A/B/C ➡️mPFS arm A v C 13.0 v 9.8 mths ➡️mPFS arm B v C 12.9 v 8.1 mths ?OS benefit? 👇Mature data needed! @ASCO @OncoAlert

Following the practice changing RASolute 302 pancreas discussion success @ASCO #ProfJenniferKnox with past Irish fellows & current fellow and colleagues from @pmcancercentre @PMResearch_UHN @RonanAndrewMcL1 @zaccoyne @graokane @EricaTsangMD @MCRCnews

Adjuvant HAIP resectable #CRCLM with low CRS #ASCO26 ➡️n=110 resection pump v 108pts resection alone ❎no ⬆️in mPFS 15.0 v 16.0 mths ➡️hepatic PFS 37.6 v 21.8mths 90 day postop mortality 4pts v 1pt No role in this setting but feasible @ASCO @OncoAlert Imp study & 👏🏻presentation

Special day #PDAC #ASCO26 ➡️RASolute302 plenary today &👇NEJM ➡️n=500, 2nd line Daraxonrasib v chemo ➡️mPFS RAS G12 7.3 v 3.5mth ➡️mOS 13.2 v 6.7mth(all) ➡️gd 3/4 AEs 61.8 v 69.6% ⭐️dawning new era⭐️ Congrats to authors! nejm.org/doi/full/10.1056/NE… @OncoAlert

Not just one but two posters for the fabulous @orlaffitz 🇮🇪#ASCO26 🎉 ➡️genomic predictors outcome frontline BTC for chemo/IO-nb impact of KRASm! #BTC Also needs RAS strategies ➡️tracking genomic evolution HER2- altered #BTC - evolving field @CholangioIre @cancertrials_ie

ASCO/AACR joint session:KRAS journey drug dvpt-to beyond G12C ➡️combining G12Ci with IO in NSCLC Nb toxicity! ➡️incredible journey of pan-RASi-1st line already ➡️Allele specific &pan-RAS combos inc degraders& vaccines ➡️how can we optimise trial design! #ASCO26 @ASCO @OncoAlert

A HUGE Round of thanks! The #OncoAlert5k 🚨Continues to Grow year after year, with a lot of new faces but also all the regulars🏃‍♂️ Thank you all of the great support! WE ARE INDEED ALL OncoAlert!! @Icro_Meattini @BalazsHalmosMD @alitimumab @MikeSerzanMD @barrosonco @DrVilmaPBarcia @DonjetaZeqa @crisonco @santcancela @golbretas @fedenichetti @crisonco @CathyEngMD @BenWestphalen @OncBrothers @graokane @realbowtiedoc @GaiaGriguolo @COR2EDMedEd @mirrorsmed @amerseburger @DrMirallas @ravikanesvaran @fabioturco92 @salvolarosa @KidneyCancer We Totally missed @to_be_elizabeth @ElisaAgostinett @nataliagandur and @CentralParkWMD @Latinamd @CathyEngMD @LaurenMachos @JooMouta2 @drteplinsky @matteolambe and many more but we look forward to seeing them at the 5k in Madrid🇪🇸 or during OUR HOMECOMING 5k in my HOME of San Antonio Tx🇺🇸for #SABCS26

Early serial ctDNA dynamics resected stage I-IV CRC ➡️observational data GALAXY; tumor informed ➡️1915 pts ctDNA-ve at 4wks ✅persistent -ve:24mth DFS ~85% ➡️~3% ve (n=56) at 12wks -benefit chemo; more stg 4 ✅serial ctDNA early prognostic info #CRC #ASCO26 @ASCO @OncoAlert

MCED testing in pop screening NHS-Galleri-RCT of 142,250 pts ➡️blood up to 3 visits ➡️aim to reduce stage III/IV Med FU 17mths ❎primary endpt not met-but ⬇️in stg4 ➡️52% PPV; 99.5% specificity ✅4 fold⬆️ in screen detected ca Huge effort from NHS #ASCO26 @ASCO @OncoAlert

very fruitful discussion after super informative presentations! @EASLnews #HCC @NaultJc @EASLedu @SherrieBhoori @graokane @BCLC_group

The OncoAlert🚨 GI faculty’s TOP 10 abstracts In GI Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior experts across #ColorectalCancer #ColonCancer #LiverCancer #PancreaticCancer and more A snapshot of what will shape GI oncology at #ASCO26 👇 🚨 OncoAlert Top 10 — #GIcancer at #ASCO26 1️⃣ LBA5 | RASOLUTE 302 — Daraxonrasib vs chemo in previously treated metastatic pancreatic adenocarcinoma 2️⃣ #4017 | FIGHT-302 — Pemigatinib in untreated unresectable/metastatic FGFR2-rearranged cholangiocarcinoma (Ph3) 3️⃣ LBA4000 | EMERALD-3 — Tremelimumab durvalumab lenvatinib TACE in unresectable HCC (Ph3) 4️⃣ #3506 | PUMP Trial — Adjuvant HAIP floxuridine in resectable colorectal liver metastases 5️⃣ LBA3500 | CIRCULATE — ctDNA-guided adjuvant therapy in Stage II colon cancer 6️⃣ LBA3503 | BREAKWATER — Encorafenib cetuximab FOLFIRI as 1L in BRAF V600E mCRC (Ph3) 7️⃣ LBA3508 | EPISODE-III — Adjuvant aspirin vs placebo in Stage III CRC post-resection (Ph3) 8️⃣ #3505 — Trastuzumab rezetecan vs SOC in chemo-refractory HER2 advanced CRC (Ph3) 9️⃣ #4006 | ATTRACTION-6 — Nivo ipi chemo as 1L in HER2− advanced gastric/GEJ cancer 🔟 #3504 | SWOG S2107 — Encorafenib cetuximab nivo in MSS BRAF V600E mCRC (Ph2) Leads @realbowtiedoc @p_ciracimd @WeOncologists Senior faculty @CathyEngMD @ARosen380 @GillSharlene @BenWestphalen @graokane Participating AF @DrVilmaPBarcia @Erman_Akkus @GIMedOnc

We are getting Closer #OncoAlert5k 🏃‍♂️➡️ at #ASCO26 Are you Ready?? Join US!!! May 30th, 2026 7am in front of the McCormick!! SIGN UP HERE 👉 buff.ly/3kvnMej @CathyEngMD @ambaleiras @graokane @BelaMrinakova @LesleyWu22 @crisonco @draandrezasouto @annapmrr73 @realbowtiedoc @amerseburger @Sapkotasuhail @malgospie @drfernandovidigal @DraAndreaBorges @Icro_Meattini @DrVilmaPBarcia @paomanca @DraMartinezLago @DrMirallas @anthonymjoshua @doconcMD @karenbythelee24 @cdanicas @barrosonco @realbowtiedoc @BenWestphalen

The International Liver Cancer Association (ILCA) Annual Conference is Sept. 3–5 in Brussels, gathering global experts advancing research, diagnosis, and management of liver cancer. Register using code ILCAAC26_CCF for 15% off: ilcalive.org/annual-conferen…